samedan logo
 
 
 
spacer
home > ebr > summer 2019 > the renaissance of microbial fermentation
PUBLICATIONS
European Biopharmaceutical Review

The Renaissance of Microbial Fermentation

Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Vladas Bumelis is the founder of Northway Biotechpharma and Chairman of the company’s Board of Directors and Advisory Board. He has extensive experience in the pharma and biotechnology industries, having previously served as General Manager of Teva Pharmaceutical Industries, Chairman of the Board for Biofa and Biotechna, and Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania. In 2004, Vladas received the Science Award of Lithuania in recognition of his achievements in the development and production of recombinant proteins. He has a PhD and MSc in chemistry, as well as a PhD in biotechnology, from Vilnius University, Lithuania.
spacer
Dr Vladas Bumelis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Ardena expands capacity to satisfy Novavax COVID vaccine demand

Gent, Belgium/December 2021: Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO), announced it will be expanding its capacity for purification and fractionation of GMP manufacturing at its site in Södertälje, Sweden. The expansion will satisfy long-term demand expected from Novavax for production of the company’s COVID-19 vaccine, among others.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement